Group Introduction
[Its Dual-Listed Companies] Joincare Pharmaceutical Group (Stock Code: 600380 GDR Code：JCARE) Livzon Pharmaceutical Group (Stock Code: 000513 Hong Kong Stock Code: 01513)
Xinxiang Haibin Pharmaceutical Co., Ltd.
Xinxang Haibin Pharmaceutical Co., Ltd. is a Sino-foreign joint venture established with joint investment from Shenzhen Haibin Pharmaceutical Co., Ltd., a subsidiary of HealthGen Biotech, and Hong Kong Tiancheng Industrial Co., Ltd.. The company's registered capital is 1.7 yuan, with total assets of 4.28 yuan. It covers an area of 120 mu, with 660 employees, including 1 doctor, 9 postgraduate students, 90 undergraduate degree holders, 2 senior professionals, and 9 intermediate professionals. The company has strong technical capabilities, management skills, and complete safety and environmental protection facilities. The company's main product is meropenem, and it has a full industrial chain layout from intermediates to preparations, giving it a strong market competitive advantage. The company passed ISO9001 and ISO14001 management system certifications in 2008, and OHSAS18001 management system certification in 2011; in 2011, it was awarded the title of High-tech Enterprise in Henan Province; and in September 2018, it obtained a drug production license. It has successively obtained 1 scientific and technological achievement of Henan Province, 1 third-prize of Henan Provincial Science and Technology Progress Award, and 1 first-prize of Xinxang Municipal Science and Technology Progress Award. Currently, it has 1 provincial engineering technology center and 1 provincial enterprise technology center, and has accumulated 17 invention patents. In May 2019, it won the 2019 Green Enterprise Management Award, and in 2021, it was rated as an A-class enterprise in the "2021-2022 Heavy Pollution Weather Pharmaceutical Industry Performance Grading" evaluation.
Xinxang Haibin Pharmaceutical Co., Ltd. passed the high-tech enterprise certification in 2011. The company owns the Xinxang Meropenem Drug Engineering Technology Research Center, the Henan Meropenem Drug Engineering Technology Research Center, and the Henan Enterprise Technology Center, among other provincial and municipal platforms.
The company attaches great importance to safety and environmental protection. In the past two years, it has continuously invested more than 30 million yuan in safety and environmental protection, adding more efficient wastewater and waste gas equipment and facilities. For wastewater treatment, it uses MVR pretreatment + H/O biological treatment process, and for VOC waste gas, it uses deep cold + membrane recovery + activated carbon adsorption + RTO combined treatment process; in terms of safety, it has built a DCS, SIS safety automation instrument system, established a dual-prevention system, etc., greatly improving the level of safety and environmental protection management and effectively ensuring the stable operation of the company's safety and environmental protection.
The company will continue to increase its investment in production facilities and safety and environmental protection construction, adopting more efficient environmental protection construction processes and higher-automation production equipment, building automated intelligent workshops, and continuing to improve the company's safety and environmental protection equipment level.
With the company's development, the group plans to transfer the production lines of meropenem, imipenem-cilastatin aseptic raw materials and raw materials for anti-chronic obstructive pulmonary disease gradually to Xinxang Haibin. 。 Currently, several projects are under planning and construction, After the completion and commissioning of all projects, Xinxang Haibin's annual operating income will reach 1 billion yuan.
Our group's goal is to develop Xinxang Haibin into a domestic research and production base for high-end raw materials.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.